NTRK1 and neuroblastoma: Previous studies have also indicated that AZ‐23 exhibited Trk kinase inhibition and efficacy in mice after oral administration in a TrkA‐driven allograft model, as well as significant tumor growth inhibition in a Trk‐expressing xenograft model of neuroblastoma [58].